Tumor Associated Neutrophils
Conditions
Brief summary
A single biomarker is not adequate to identify patients with colorectal cancer (CRC) who have the potential to benefit from adjuvant therapy, presumably owing to the complexity of tumor-infiltrating immune cells (TIICs). The density and spatial organization of TIICs has not been definitely established to explore their predictive value. This study aimed to investigate the prognostic significance of TIICs and its biological predictive value in CRC.
Interventions
OTHERNo different intenvention
No different intenvention
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Voluntarily sign a written ICF. 2. The Eastern Cancer Collaborative Organization (ECOG) has a physical fitness score of 0 or 1. 3. The expected survival period is ≥ 3 months. 5\. Subjects diagnosed with metastatic colorectal adenocarcinoma by histology or cytology. 6\. Colorectal cancer patients who have not received systematic anti-tumor therapy in the past.
Exclusion criteria
1. Subjects suffered from other malignant tumors within 3 years before enrollment, except for cured local tumors (such as basal cell skin cancer, squamous cell skin cancer, superficial bladder cancer, cervical carcinoma in situ, etc.). 2. Simultaneously enroll in another clinical study, unless it is an observational, non-interference clinical study or a follow-up period of an intervention study. 3. Received systematic anti-tumor therapy (chemotherapy) within 3 weeks prior to the first administration
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | From date of operation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months | From date of operation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months |
Outcome results
None listed